These data suggest that the disruption of lipid metabolism (hyperlipidemia) can accelerate the production of FABP4+ fibroblasts, which are significantly increased when there is coexisting hypertension compared to hypertension or hyperlipidemia alone, thus accelerating myocardial fibrosis. The gene discussed is FABP4; the disease is hyperlipidemia.